Cancer Research The Future of Cancer Research: Science and Patient Impact  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 44, 166-171, January 1, 1984]
© 1984 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Welsch, C. W.
Right arrow Articles by Aylsworth, C. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Welsch, C. W.
Right arrow Articles by Aylsworth, C. F.

Retinoid Feeding, Hormone Inhibition, and/or Immune Stimulation and the Progression of N-Methyl-N-nitrosourea-induced Rat Mammary Carcinoma: Suppression by Retinoids of Peptide Hormone-induced Tumor Cell Proliferation in Vivo and in Vitro1

Clifford W. Welsch2, Jane V. DeHoog, Karen M. Scieszka and Charles F. Aylsworth

Department of Anatomy, Michigan State University, East Lansing, Michigan 48824

Female Sprague-Dawley rats were treated at 50 and 57 days of age with 2.5 mg per 100 g body weight of N-methyl-N-nitrosourea (MNU). At 60 days of age, the animals were divided into eight groups (40 rats/group) and treated as follows: (a) controls; (b) immune stimulation (IS); (c) hormone inhibition (HI); (d) HI + IS; (e) retinyl acetate feeding (RA); (f) RA + IS; (g) RA + HI; and (h) RA + HI + IS. IS treatment was accomplished by three i.p. injections (at 1, 3, and 5 weeks after carcinogen treatment) of a mixture of cell particulate preparations from pooled MNU-induced rat mammary carcinomas and Freund's (complete) adjuvant. HI treatment consisted of daily s.c. injections of tamoxifen (12.5 to 25.0 µg/100 g body weight) and CB-154 (200 to 400 µg/100 g body weight), and RA treatment consisted of daily feeding of retinyl acetate (1.0 mM). Both RA alone and HI alone significantly (p < 0.01 to 0.001) reduced mammary carcinoma incidence; HI treatment was significantly (p < 0.01) more effective than RA treatment. The combination of RA + HI was significantly (p < 0.01) superior to either treatment alone; RA + HI treatment virtually completely blocked the development of mammary carcinomas at termination of study (a total of only 2 mammary carcinomas was observed in the RA + HI groups of rats at 1 year after carcinogen treatment). IS treatments did not significantly influence mammary carcinoma incidence, either alone or in combination with RA and/or HI.

Female Sprague-Dawley rats given MNU and subsequently treated daily for 4 weeks with the prolactin secretion-stimulating drug haloperidol (0.05 mg/100 g body weight) responded with a significant (p < 0.001) increase in mammary carcinoma development when compared with control rats. RA treatment of haloperidol-treated rats significantly (p < 0.001) blocked the stimulatory effect of haloperidol on mammary carcinoma development. The addition of insulin (5.0 µg/ml) to the culture media of 2-day organ cultures of MNU-induced rat mammary carcinomas resulted in a significant (p < 0.05) stimulation of [3H] thymidine incorporation into DNA of the cultured cells. Retinoic acid (1 x 10-6 M) significantly (p < 0.05) blocked the stimulatory effect of insulin on [3H]thymidine incorporation into DNA; retinoic acid alone did not significantly affect [3H]thymidine incorporation into DNA.

The results of this study demonstrate a striking prevention of the development and progression of MNU-induced rat mammary carcinomas by a combination of two biological response modifier treatments, i.e., RA and HI. Retinoid-induced suppression of peptide hormone-induced stimulation of mammary carcinoma cells in vivo and in vitro has also been demonstrated, suggesting a mechanism by which retinoids may suppress the progression of rat mammary carcinomas.

1 This research was supported by USPHS Contract NO1-CP-05717 from the Division of Cancer Cause and Prevention, National Cancer Institute.

2 To whom requests for reprints should be addressed.

Received 7/15/83. Accepted 10/ 6/83.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1984 by the American Association for Cancer Research.